Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience

摘要: Nimotuzumab is a humanized anti-EGFR IgG1 monoclonal antibody and demonstrates better safety profile than other antibodies due to its intermediate affinity. Since it was approved in China for the treatment of nasopharyngeal cancer (NPC), has been widely used NPC many clinical trials types. However, optimal dose administration frequency nimotuzumab that should be which kind patients will more benefited from still unknown. In this retrospective study, 205 advanced with colorectal cancer, esophageal head neck gastric non-small cell lung or cancers mainland China, treated combination chemotherapy, were enrolled. Over 60% these received > 6 doses ≥ 400 mg/week as maintenance therapy. It well tolerated real-life patients. This report age, sex previous might potential predictive factors survival, 200 benefit Using stratification analysis may form differential strategy maximize different epithelial tumors.